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Malaria parasites replicate within a parasitophorous vacuole (PV) in red blood cells (RBC). Progeny 27 
merozoites egress upon rupture of first the PV membrane (PVM) then poration and rupture of the RBC 28 
membrane (RBCM). Egress is protease-dependent1, but none of the effector molecules that mediate 29 
membrane rupture has been identified and it is unknown how sequential rupture of the two 30 
membranes is controlled. Minutes before egress, the parasite serine protease SUB1 is discharged into 31 
the PV2-6 where it cleaves multiple substrates2,5,7-9 including SERA6, a putative cysteine protease10-12. 32 
Here we show that Plasmodium falciparum parasites lacking SUB1 undergo none of the morphological 33 
transformations that precede egress and fail to rupture the PVM. In contrast, PVM rupture and RBCM 34 
poration occur normally in SERA6-null parasites but RBCM rupture does not occur. Complementation 35 
studies show that SERA6 is an enzyme that requires processing by SUB1 for its function. RBCM rupture 36 
is associated with SERA6-dependent proteolytic cleavage within the actin-binding domain of the major 37 
RBC cytoskeletal protein β-spectrin. We conclude that SUB1 and SERA6 play distinct, essential roles in a 38 
coordinated proteolytic cascade that enables sequential rupture of the two bounding membranes and 39 
culminates in RBCM disruption through rapid, precise, SERA6-mediated disassembly of the RBC 40 
cytoskeleton. 41 
 42 
Malaria, caused by parasitic protozoa of the genus Plasmodium, causes over 400,000 deaths per 43 
annum. With widespread resistance to most antimalarial drugs, there is a need to better understand 44 
the biology of the parasite, especially the species responsible for most fatalities, Plasmodium 45 
falciparum. Asexual blood stage parasites proliferate within RBC. Following each cycle of intracellular 46 
development (lasting ~48 h in P. falciparum) the PVM and RBCM rupture to allow egress of 47 
merozoites which invade fresh RBC. 48 
Egress comprises several rapidly successive steps. Following biogenesis of intracellular 49 
merozoites by segmentation of the mature schizont, the PVM becomes permeable, allowing mixing of 50 
the contents of the PV and residual RBC cytoplasm6. Within the ensuing minutes, the parasite cGMP-51 
dependent protein kinase PKG is activated to trigger discharge of SUB1, a subtilisin-like protease, from 52 
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merozoite secretory organelles called exonemes3,4. In the PV lumen, SUB1 proteolytically modifies 53 
several merozoite surface and PV proteins2,5,7,8, including SERA6, which is cleaved to release a central 54 
domain with homology to papain-like (clan CA, family C1) cysteine peptidases10. Within ~10 minutes 55 
of SUB1 discharge, the PV abruptly swells whilst the entire infected RBC transforms from an irregular 56 
to a roughly spherical ‘flower’ or rounded-up structure13,14. The PVM then fragments into 57 
multilamellar vesicles, closely followed by collapse and poration (permeabilisation) of the RBCM6,14,15. 58 
Within seconds the RBCM ruptures, allowing merozoite release16. Inhibitors of PKG block SUB1 59 
discharge and all stages of egress subsequent to the initial PVM permeabilisation step3,5,6,17. In 60 
contrast, the broad-spectrum cysteine protease inhibitor epoxysuccinyl-L-leucylamido(4-61 
guanidino)butane (E64), which does not inhibit SUB1 activity3, prevents neither PVM rupture nor 62 
RBCM collapse and poration, but blocks the final step of RBCM rupture6,14,15,18. 63 
We used the rapamycin (RAP)-inducible dimerizable Cre recombinase (DiCre) system19,20 to 64 
conditionally excise either a segment of the SUB1 gene encoding crucial catalytic residues, or the 65 
entire SERA6 coding sequence (Fig. 1a). In each case, PCR (Fig. 1a) and Western blot (Fig. 1b and 66 
Supplementary Fig. 1) demonstrated rapid and efficient RAP-induced excision of the floxed DNA 67 
sequences and ablation of SUB1 or SERA6 expression. Immunofluorescence analysis (IFA) confirmed 68 
loss of SUB1 in 99.8% of schizonts (of 5,056 examined) by the end of the erythrocytic cycle (cycle 0) in 69 
which the parasites were RAP-treated (Fig. 1c). Both SUB1-null (ΔSUB1) and ΔSERA6 parasites formed 70 
morphologically normal schizonts at the end of cycle 0, showing that neither gene is required for 71 
intracellular development (Fig. 1c). However, over the ensuing erythrocytic cycles there was a 72 
dramatic reduction in replication rates of the RAP-treated cultures (Fig. 1d). Monitoring over 8-10 73 
erythrocytic cycles showed that the initially minor population of non-excised parasites gradually 74 
overgrew these cultures whilst the ΔSUB1 or ΔSERA6 parasites disappeared (Fig. 1e), indicating a 75 
severe defect. To further assess the impact of gene disruption we used a plaque assay12 which 76 
captures successive rounds of replication by individual parasite clones. Substantial reductions in 77 
plaque numbers were observed in RAP-treated cultures (Fig. 1f and reference 12), and the few 78 
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plaques generated were found to arise from the small population of non-excised parasites 79 
(Supplementary Fig. 2 and reference 12). These results suggested that both the SUB1 and SERA6 80 
genes are required for in vitro parasite growth. 81 
To confirm that loss of viability was a consequence of gene disruption, plasmids for episomal 82 
expression of wild-type (WT) SUB1 or SERA6 transgenes were introduced into the (non-RAP-treated) 83 
SUB1HA3:loxP or SERA6:loxP parasites respectively. The resulting lines were RAP-treated to disrupt 84 
the chromosomal genes, then immediately analysed by plaque assay in comparison with RAP-treated 85 
control lines harbouring ‘empty’ plasmid. As shown in Fig. 1f, lines carrying episomal WT SUB1 or 86 
SERA6 transgenes produced significantly more plaques following disruption of the chromosomal 87 
genes than similarly-treated parasites harbouring empty plasmid. Parasites expanded from plaques 88 
produced by RAP-treated parasites carrying the episomal SUB1 or SERA6 transgenes had lost the 89 
respective chromosomal gene as expected and so were likely relying solely on the episomal gene 90 
copies (Supplementary Fig. 3). Crucially, the ΔSERA6 growth defect could not be rescued by a mutant 91 
SERA6 transgene possessing an Ala substitution of the predicted catalytic Cys644 codon (expected to 92 
ablate enzyme activity10) (Fig. 1f). Similarly, the ΔSERA6 defect was not complemented by a SERA6 93 
mutant in which the SUB1 processing sites flanking the papain-like domain were modified by Leu 94 
substitutions of the P1 and P2 residues upstream of each scissile bond; these mutations prevent 95 
SUB1-mediated cleavage10 (Fig. 1f). Collectively, these findings confirmed that SUB1 and SERA6 are 96 
indispensable and indicated that SERA6 is an enzyme that requires proteolytic processing by SUB1 to 97 
perform its function. 98 
To examine egress of ΔSUB1 and ΔSERA6 parasites, mature schizonts were incubated with 99 
the PKG inhibitor (4-[7-[(dimethylamino)methyl]-2-(4-fluorphenyl)imidazo[1,2-α]pyridine-3-100 
yl]pyrimidin-2-amine (compound 2; C2), which reversibly blocks development just prior to egress, 101 
resulting in accumulation of ‘stalled’ segmented schizonts. Wash-out of the inhibitor allows rapid 102 
progress to rupture, enabling live microscopic examination of multiple egress events over the ensuing 103 
~10-30 minutes3,5,9. As shown in Fig. 2a and Supplementary Movie 1, ΔSUB1 parasites underwent 104 
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none of the morphological changes associated with egress, with no signs of PVM swelling, rounding 105 
up, apparent PVM rupture (as indicated by loss of differential interference contrast and increased 106 
mobility of the intracellular merozoites), or RBCM rupture. Indeed, the ΔSUB1 phenotype was 107 
indistinguishable from that produced by continued incubation with C2, suggesting that SUB1 is 108 
required for all the egress-related transformations that follow PKG activation. This egress defect was 109 
completely rescued by the WT SUB1 transgene (Supplementary Movie 2). As expected, proteolytic 110 
processing of the SUB1 substrates SERA52, SERA6 and merozoite surface protein-1 (MSP1)5,7 was 111 
ablated in the ΔSUB1 parasites (Fig. 2b). However, IFA using antibodies to AMA1, a protein released 112 
onto the merozoite surface from micronemes (which are distinct from the exonemes in which SUB1 is 113 
stored2,3) showed that microneme discharge occurred in the trapped ΔSUB1 merozoites (Fig. 2c). Like 114 
SUB1 discharge, AMA1 discharge is blocked by PKG inhibitors3, so this confirmed reversal of the C2-115 
mediated PKG inhibition in these experiments. 116 
P. falciparum is generally maintained in static culture. To address whether invasion-117 
competent merozoites could be liberated by fluid shear stress, SUB1HA3:loxP schizonts were cultured 118 
overnight with fresh RBC under vigorously shaking conditions. As expected21, shaking enhanced 119 
increases in parasitaemia in mock-treated SUB1HA3:loxP cultures (Fig. 2d), likely due to more efficient 120 
merozoite dissemination and RBC invasion. However, shaking had no impact on the low proliferation 121 
rate of RAP-treated (ΔSUB1) parasites, indicating that SUB1 is essential for release of invasive 122 
merozoites. 123 
In contrast to the ΔSUB1 phenotype, ΔSERA6 schizonts displayed normal rounding up as well 124 
as the increases in merozoite visibility and mobility thought to indicate PVM rupture; however, RBCM 125 
rupture did not occur (Fig. 2e and Supplementary Movie 3). Introduction of the complementing WT 126 
SERA6 expression plasmid restored egress (Supplementary Movie 4). IFA confirmed microneme 127 
discharge in theΔSERA6 schizonts (Fig. 2f) whilst Western blot revealed normal SUB1 activity (Fig. 2g). 128 
Similar to the ΔSUB1 parasites, shaking did not enhance the replicative capacity of ΔSERA6 parasites 129 
(Fig. 2h). 130 
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Upon PVM lysis, but just prior to RBCM rupture, the RBCM suddenly becomes permeable to 131 
the F-actin binding peptide phalloidin9,14,22. To definitively establish the fate of the PVM in the 132 
mutants and to examine the timing and efficiency of RBCM poration, SUB1HA3:loxP and SERA6:loxP 133 
parasites were transfected prior to RAP-treatment with a plasmid for constitutive expression of the 134 
PVM protein EXP123 fused to mCherry, fluorescently labelling the PVM (Supplementary Fig. 4). 135 
Simultaneous DIC and fluorescence video-microscopy in the presence of fluorescent wheat germ 136 
agglutinin (which labels the RBCM) and fluorescent phalloidin, confirmed that neither PVM rupture 137 
nor RBCM poration took place in ΔSUB1 parasites (Fig. 3a and Supplementary Movie 5). In contrast, 138 
RBCM poration occurred normally in the ΔSERA6 parasites upon PVM rupture. Examination of the 139 
arrested ΔSUB1 parasites by transmission electron microscopy (TEM) confirmed an intact PVM and 140 
RBCM indistinguishable from C2-arrested schizonts (Fig. 3b and Supplementary Fig. 5). In contrast, 141 
scanning EM (Fig. 3c) and TEM (Fig. 3d and Supplementary Fig. 5) of arrested ΔSERA6 parasites 142 
revealed merozoites and PVM fragments within an intact but collapsed and evacuated RBCM, as 143 
previously observed in WT parasites arrested by E646. 144 
Our observation that egress proceeded normally in the ΔSERA6 parasites up to the point of 145 
RBCM rupture suggested that SERA6 mediates RBCM breakdown. To test this model and further 146 
dissect the ΔSERA6 defect, we performed a proteomic comparison of mock- and RAP-treated 147 
SERA6:loxP schizonts. SDS PAGE (Fig. 4a) detected a high molecular mass species that appeared within 148 
20 minutes in soluble fractions of mock-treated parasites allowed to undergo egress, identified as a 149 
truncated form of the major RBC cytoskeleton protein β-spectrin. Further quantitative tandem mass 150 
spectrometry (LC-MS/MS) analysis revealed the concomitant appearance of one or more lower 151 
molecular mass polypeptides comprising the N-terminal calponin homology (CH) domain of the β-152 
spectrin actin-binding domain (ABD) (Fig. 4b and Supplementary Fig. 6). This suggested that RBCM 153 
rupture is associated with proteolytic cleavage of β-spectrin near its N-terminus and release of the 154 
cleavage products from the cytoskeleton (which is generally insoluble in aqueous buffers). Western 155 
blot (Fig. 4c) and pull-downs using spectrin-specific monoclonal antibodies (mAbs) combined with LC-156 
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MS/MS (Fig. 4d and Supplementary Fig. 7) confirmed and extended this, showing that RBCM rupture 157 
is accompanied by extensive SERA6-dependent cleavage of β-spectrin at two closely-spaced sites 158 
(Gln167-Glu168 and Gln165-Thr166) between the CH1 and CH2 domains of the ABD, releasing the 159 
CH1 domain as a ~17 kDa fragment and resulting in solubilisation of the truncated β-spectrin along 160 
with some α-spectrin. The released CH1 domain co-purified with human β-actin, likely also derived 161 
from the RBC cytoskeleton (Fig. 4d and Supplementary Fig. 8). No proteolytic cleavage of the other 162 
major RBC cytoskeletal components α-spectrin and protein 4.1R was detectable, although limited 163 
SERA6-dependent cleavage of ankyrin was evident (Supplementary Fig. 9). Strikingly, β-spectrin 164 
cleavage was never observed in ΔSERA6 parasites, even upon mechanical, hypotonic, freeze-thaw or 165 
detergent-mediated rupture of the schizonts (Fig. 4e), showing that cleavage was not due to lysis per 166 
se and implicating SERA6 as the enzyme responsible. The β-spectrin CH1 domain mediates key 167 
interactions between each end of the α2β2-spectrin tetramers that constitute the bulk of the 168 
cytoskeleton, and short β-actin filaments (together with protein 4.1R) at the junctional complexes 169 
that link the RBC cytoskeleton to its plasma membrane, providing the latter with structural integrity 170 
(Fig. 4f)24-26. Cleavage is therefore predicted to unravel the cytoskeleton with resulting RBCM 171 
destabilisation (Fig. 4g). Spectrin tetramers also bind the plasma membrane through interactions with 172 
the ankyrin complex24, so the limited cleavage of ankyrin might facilitate release of the cleavage 173 
products and associated proteins from the cytoskeletal complex.  174 
Our findings ascribe the physico-mechanical processes underlying malarial egress to two 175 
parasite proteases that act rapidly and sequentially within the same, PKG-regulated pathway. SUB1 is 176 
required for all the structural changes following PKG activation, including rounding up, PVM lysis, 177 
RBCM poration and RBCM rupture. SERA6 is not required for PVM rupture or RBCM poration, but 178 
accomplishes the final step of RBCM rupture primarily through targeted cleavage of β-spectrin at a 179 
site that is essential for cytoskeletal stability. PVM rupture is unlikely to be directly mediated by 180 
protease activity, so SUB1 may regulate this by activating one or more membrane lytic effectors that 181 
mediate PVM rupture, as well as perhaps RBCM poration. These could include pore-forming proteins 182 
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or phospholipases, both implicated in egress of other parasite developmental stages22,27,28. That 183 
SERA6 function requires SUB1-mediated processing is consistent with processing representing 184 
activation of SERA6, as previously suggested10. The striking similarity between the ΔSERA6 phenotype 185 
and that produced by treatment with E646,14,18 supports this and suggests that SERA6 is the major 186 
target of E64 in schizonts. Importantly, our study proves that host RBC calpain-1, previously 187 
implicated by others in egress29, is not sufficient for RBCM rupture since its expression should be 188 
unmodified in ΔSERA6 parasites. 189 
All Plasmodium species, including the other major pathogens P. vivax and P. knowlesi, express 190 
orthologues of SUB1 and SERA6. Drugs that inhibit these proteases, particularly if combined with 191 
inhibitors of PKG30, would target consecutive, interdependent steps in the egress pathway and so 192 
could form a new class of antimalarial designed to prevent parasite proliferation and disease. 193 
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Methods 194 
Reagents and antibodies 195 
Anonymised human blood was obtained from the UK National Blood Transfusion Service. The 196 
antifolate WR99210 was from Jacobus Pharmaceuticals (New Jersey, USA). Blasticidin, rapamycin and 197 
E64 (Sigma) were used as described previously9,19. Compound 2 was kindly provided by Dr Simon 198 
Osborne (LifeArc, SBC Open Innovation Campus, Stevenage UK); stocks (10 mM) were stored in DMSO 199 
at -20oC and used throughout at a final concentration of 1 μM. Alexa Fluor 488 phalloidin and Alexa 200 
Fluor 647-conjugated WGA was from Thermofisher. The β-spectrin-specific mAbs B-1, B-2 and VD4, 201 
the α-spectrin-specific mAb 17C7, and mAbs B-11 and 8C3 specific for protein 4.1R and ankyrin 202 
respectively were all from Santa Cruz Biotechnology. Monoclonal antibody 7.7 (anti-EXP2) was from 203 
the European Malaria Reagent Repository (http://www.malariaresearch.eu/), contributed by Jana 204 
McBride. The polyclonal anti-mCherry antibody (ab167453) was from Abcam. The P. falciparum 205 
MSP1-specific mAb 89.1 has been described previously31, as have rabbit antisera to P. falciparum 206 
SERA59, SERA610, SUB132 and AMA133. Phusion high-fidelity DNA polymerase and restriction enzymes 207 
were from New England BioLabs, and a Rapid DNA Ligation Kit (Roche) was used for DNA ligation. 208 
 209 
Parasite maintenance, synchronization and transfection 210 
The DiCre-expressing P. falciparum clone 1G5DC19 was maintained at 37°C in human RBC in RPMI 211 
1640 medium containing Albumax (Invitrogen) supplemented with 2 mM L-glutamine. Cultures were 212 
routinely monitored by microscopic examination of Giemsa-stained thin blood films and synchronised 213 
by standard procedures34. As required, mature schizonts were isolated by centrifugation over 214 
cushions of 70% (v/v) isotonic Percoll (GE Healthcare Life Sciences) as described34. Invasion assays 215 
were performed as previously described3,5, either in static culture or in a shaking incubator revolving 216 
at 225 rpm. For transfection of plasmid constructs, ~108 Percoll-enriched schizonts were suspended in 217 
100 μl of P3 primary cell solution containing 10 μg of DNA and electroporated with an Amaxa™ P3 218 
primary cell 4D Nucleofector™ X Kit L (Lonza), using program FP158 as previously described5. Growth 219 
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medium was supplemented ~20 h post transfection with WR99210 (2.5 nM) or blasticidin (2 μg/ml). 220 
Once sustained growth of drug-resistant parasites was observed, drug cycling was used to enrich for 221 
genomic integration of plasmid constructs as previously described2. Transgenic parasite clones 222 
SUB1HA3:loxP and SERA6:loxP were obtained by limiting dilution cloning in microplates at a 0.1-0.3 223 
parasite per well. Parasite genomic DNA (gDNA) for genotype analysis was extracted using a Qiagen 224 
DNeasy Bood and Tissue kit and analyzed by PCR using Kappa 2G Fast HotStart ReadyMix (Kappa 225 
Biosciences). 226 
 227 
Immunofluorescence and Western blot  228 
For IFA, air-dried thin films of parasite cultures were fixed in paraformaldehyde, permeabilized, then 229 
probed with relevant primary antibodies as described previously10. Secondary Alexa Fluor 488- or 594-230 
conjugated antibodies specific for human, rabbit or mouse IgG (Invitrogen), or Alexa Fluor 594-231 
conjugated streptavidin (Invitrogen) were used at a dilution of 1:1000. Samples were mounted in 232 
Vectashield antifade mounting medium (Vector Laboratories) containing DAPI. Images were acquired 233 
using a Nikon Eclipse and NIS Elements software (Nikon, Japan), using identical exposure conditions 234 
for all samples being compared. Western blots were performed as described previously33. For 235 
detection of HA3-tagged SUB1, the rat anti-HA mAb 3F10 (Sigma) was used at a 1:1000 dilution, 236 
followed by biotin-conjugated anti-rat antibody (Roche) (1:8,000 dilution), then horseradish 237 
peroxidase (HRP)-conjugated streptavidin (Sigma) (1:10,000 dilution). Immobilon Western 238 
Chemiluminescent HRP Substrate (Millipore) was used according to the manufacturer’s instructions, 239 
and blots were visualised and documented using a ChemiDoc Imager (Bio-Rad) with Image Lab 240 
software (BioRad). 241 
 242 
Generation of integration, complementation and expression plasmids 243 
SUB1HA3:loxP and SERA6:loxP parasite clones were generated by single crossover homologous 244 
recombination into the 1G5DC genome using integration plasmids pHH1_SUB1HA3_loxP and 245 
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pHH1_S6chimera_loxP respectively. In both cases, correct transcriptional regulation of the modified 246 
gene was assured by placement of the 3’ UTR of the P. berghei dihydrofolate reductase thymidylate 247 
synthase (PbDT) gene downstream of the floxed coding sequence19. To target the SUB1 gene, a 248 
chimeric gene fragment with a native 5’ portion and a recodonised 3’ segment was constructed by 249 
first amplifying the 5’ sequence from P. falciparum 3D7 gDNA using primers JT-S1endo-F and JT-S1CO-250 
R, whilst the recodonised region was amplified from plasmid pFastBac-sPfSUB1wt32 using primers JT-251 
S1CO-F and JT-S1synth-R. The amplicons were then fused in frame by inclusion of both in a fresh PCR 252 
reaction including primers JT-S1endo-F and JT-S1synth-R, and the product cloned into pGEM-T 253 
(Promega). A segment of this fragment was then excised using HindIII and KpnI and replaced with a 254 
similarly-digested loxP-containing synthetic intron (loxPint)20 (Geneart). This intermediate vector was 255 
digested with HpaI and Xho I to liberate the SUB1 sequence which was ligated into 256 
pHH1_sera5_LoxP119 digested with the same enzymes to generate  pHH1_SUB1HA3_loxP. Integration 257 
of this construct into the 1G5DC SUB1 locus by homologous recombination was detected by 258 
diagnostic PCR with primers JT111-1p and JT111-2p, and the floxed or excised SUB1 locus was 259 
detected by PCR using primers JT111-1p and JT111-3p. 260 
To generate pHH1_S6chimera_loxP, a chimeric SERA6 gene fragment was excised from 261 
plasmid MWS36 by digestion with HpaI and NcoI. Full details of plasmid MWS36 will be provided in a 262 
separate manuscript (M. Shea and M. Blackman, in preparation). The chimeric SERA6 sequence 263 
comprised a 920 bp  5’ portion of endogenous coding sequence starting from within the first intron 264 
followed by synthetic recodonised SERA6 cDNA sequence extending to the stop codon. Plasmid 265 
pHH1_sera5_LoxP1 was digested with HindIII, ‘blunted’ with T4 DNA polymerase, then further 266 
digested with NcoI before ligation to the chimeric SERA6 fragment excised from MWS36, generating 267 
pHH1_S6chimera_loxP. Integration of this construct by homologous recombination into the 1G5DC 268 
genome (which already contains a single genomic loxP site upstream of the SERA6 locus19) was 269 
designed to introduce a second loxP site downstream of the SERA6 stop codon. Correct integration 270 
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was detected by diagnostic PCR using primers SERA6-5’UTRb and SERA6-37, whilst the floxed or 271 
excised SERA6 locus was detected with primers S65’UTRb-2 and S6EndoEx2Rev. 272 
For generation of plasmid constructs designed for transgenic expression of SERA6, a chimeric 273 
coding sequence and native SERA6 promoter was excised from plasmid MW28 and ligated into SalI 274 
and NcoI digested plasmid pDC-mCherry-MCS (a modification of pDC2-mCherry9), giving rise to pDC2-275 
wtSERA6 (WT SERA6). The chimeric SERA6 sequence comprised 979 bp of putative promoter 276 
sequence upstream of the native SERA6 ATG start codon, as well as  477 bp of the 5’ segment of the 277 
coding sequence (including the first intron) and a synthetic recodonised SERA6 cDNA10 encoding the 278 
remainder of the ORF. Full details of plasmid MWS28 will be provided in a separate manuscript (M. 279 
Shea and M. Blackman, in preparation). Site-directed mutagenesis and sub-cloning steps were then 280 
used as previously described10 to generate identical constructs containing di-Leu substitutions of the 281 
P1 and P2 positions at the SUB1 processing sites 1 and 2 in SERA6,  as well as a Cys644Ala substitution 282 
of the active site nucleophile, giving rise to plasmids pDC2-SERA6-uncleavable (Uncleavable SERA6) 283 
and pDC2-SERA6_Alamut  (Cys644Ala) respectively. 284 
For transgenic expression of WT SUB1 the pDC-mCherry-MCS plasmid was modified such that 285 
the blasticidin deaminase (BSD) drug selection cassette and mCherry reporter gene were expressed 286 
from a single promoter by the use of the ribosomal T2A skip peptide. To do this, the BSD cassette was 287 
excised from pDC2-mCherry_MCS with ApaI and SacI and the backbone re-ligated. The mCherry ORF 288 
was then excised by digestion with AvrII and XhoI and replaced with a synthetic gBlock (IDT) 289 
comprising the mCherry and BSD ORFs separated by the T2A sequence. This resulted in construct 290 
pDC2-mCherryT2ABSD_MCS in which these ORFs remained under control of the constitutive P. 291 
falciparum calmodulin (CAM) promoter (which remained from the original mCherry expression 292 
cassette). This vector was then linearized with SnaBI. The P. falciparum SUB1 promoter sequence was 293 
amplified from P. falciparum 3D7 gDNA using primers PfSUB1_prom_for_infu and 294 
PfSUB1_prom_rev_infu. Primers PfSUB1_synth_for_infu and PfSUB1_synth_rev_infu were used to 295 
amplify the recodonised synthetic SUB1 ORF from pFastBac-sPfSUB1wt and primers PbDT3UTR-296 
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for_infu and PbDT3UTR-for_infu were used to amplify the PbDT 3’ UTR from pDC2-mCherry_MCS. 297 
Primers included complementary overhangs such that all 3 fragments could then be finally assembled 298 
into the  linearized pDC2-mCherryT2ABSD_MCS backbone in a single step using an InFusion HD 299 
Cloning Kit (Clontech), generating pDC2-mCherryT2ABSD_wtSUB1 (WT SUB1). 300 
For episomal transgenic expression of an EXP1mCherry fusion protein (to fluorescently label 301 
the PVM), a synthetic intronless DNA fragment encoding mCherry fused to the C-terminus of the P. 302 
falciparum EXP1 (PlasmoDB ID PF3D7_1121600) via a polyglycine-alanine linker (GAGGGGGGGGA) 303 
was obtained from Geneart. This was sub-cloned into vector pCR-Blunt using the ZeroBlunt PCR 304 
cloning kit (Invitrogen). The resulting plasmid was digested with AvrII and XhoI before ligating the 305 
EXP1mCherry fragment into pDC-mCherry-MCS in the place of the mCherry ORF, generating pDC2-306 
EXP1-mCherry.  307 
 308 
Parasitaemia quantitation by flow cytometry 309 
Parasites were fixed in 4% paraformaldehyde, 0.02% glutaraldehyde for 30 min at 37°C, diluted five-310 
fold in phosphate-buffered saline, then stored at 4°C until required. Cells were stained with Hoechst 311 
33342 (diluted 1:10,000) for 30 min at 37°C, then parasitaemia determined using a Fortress or FACS 312 
Aria (BD) flow cytometer as previously described9. Briefly, samples were initially screened using 313 
forward and side scatter parameters and gated for RBC (Supplementary Fig. 10). Ultraviolet light with 314 
a violet filter (450/50 nm) was then used  to determine the proportion of infected cells in 100,000 315 
RBC. 316 
 317 
Time-lapse DIC and fluorescence video microscopy 318 
Viewing chambers for live microscopy were constructed as described previously3,5 by adhering 22 x 64 319 
mm borosilicate glass coverslips to microscope slides. Mature Percoll-enriched schizonts were 320 
incubated for 3-4 h at 37°C in complete medium supplemented with C2 (1 μM), then ~5 x 107 321 
schizonts were rapidly washed twice in gassed warm complete medium lacking C2, pelleting at 1,800 322 
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x g for 1 min. The cells were suspended in 50 μl of the same medium and introduced into the pre-323 
warmed viewing chamber on a temperature-controlled microscope stage held at 37oC on a Nikon 324 
Eclipse Ni-E wide-field microscope fitted with a Hamamatsu C11440 digital camera and Nikon N Plan 325 
Apo λ 100x/1.45NA oil immersion objective. Images (DIC alone or simultaneous DIC and fluorescence) 326 
were taken at 5-10 s intervals over a total of 20-60 min, then annotated and exported as TIFFs, AVI or 327 
QuickTime movies using  Nikon NIS-Elements software.  328 
 329 
Parasite plaque assays 330 
Plaque assays were performed by dispensing parasite cultures (200 μl at a haematocrit of 0.75%) into 331 
flat-bottomed 96-well microplates, as described12. Plates were imaged 14-16 days later to detect 332 
plaque formation, using an Epson Perfection V750 Pro high resolution flat-bed scanner in top-down 333 
transmission light mode. When required, parasites from wells containing a single plaque were 334 
expanded by transferring initially to round-bottomed microplate wells to aid medium changes, before 335 
further expansion into culture flasks. 336 
 337 
Scanning electron microscopy 338 
Mature arrested ΔSERA6 schizonts, or WT control schizonts allowed to reach the point of egress in 339 
the presence of E64 (50 μM) were fixed in 2.5% glutaraldehyde, washed, osmicated (1% OsO4 for 16 340 
h), dehydrated, critical point dried and sputter coated with 5 nm gold for scanning EM. Images were 341 
collected on a JEOL JSM 7610F with 2.6 kV accelerating voltage. 342 
 343 
Transmission electron microscopy 344 
Mature schizonts were fixed for 5 min at 37oC in 2% formaldehyde (ΔSERA6 and E64-arrested 345 
schizonts) or 2% formaldehyde 1% glutaraldehyde (ΔSUB1 and C2-arrested WT schizonts), pelleted by 346 
centrifugation, mixed with 20% (w/v) dextran in complete medium containing bakers’ yeast, then 347 
frozen using a HPM100 high-pressure freezer (Leica). Vitrified cells were freeze-substituted using a 348 
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EM AFS2 (Leica) into Lowicryl HM20 resin (EMS) with 0.2% (w/v) uranyl acetate and cut into 250 nm 349 
or 120 nm sections using a UC7 microtome (Leica). Sections were placed on glow-discharged carbon-350 
coated copper London Finder grids (EMS) with 10 nm Protein A-Au fiducials (EMS) and post-stained 351 
with 0.2% (w/v) uranyl acetate and 4% (w/v) lead citrate. Images and tomograms were recorded using 352 
a Model 2040 dual-axis tomography holder (Fischione Instruments) on a Tecnai F20 200 kV field 353 
emission gun electron microscope (FEI) equipped with a DE20 camera (Direct Electron), or a Tecnai 354 
T12 120 kV field emission gun electron microscope (FEI) equipped with a 4kx4k Ultrascan 4000 CCD 355 
camera (Gatan). Dual-axis tilt series were acquired from -60° to +60° with an increment of 2° using 356 
SerialEM35 and processed using IMOD36 with nonlinear anisotropic diffusion filtering. 357 
 358 
Proteomic analysis and pull-downs 359 
Mature mock- or RAP-treated mature SERA6:loxP schizonts were incubated for ~4 h at 37°C in 360 
complete medium supplemented with C2, then washed once in gassed, warm protein-free medium 361 
containing C2 before rapidly washing twice in similar medium lacking C2, pelleting at 1,800 x g for 1 362 
min. The cells were suspended at high density (~1 x 109/ml) in warm protein-free medium lacking C2 363 
and incubated for just 20 min at 37°C to allow progress to egress. The entire samples were then snap-364 
frozen in liquid N2.  365 
For global proteomic analysis, samples were thawed by the addition of an equal volume of 366 
ice-cold water containing protease inhibitors (cOmplete™ Protease Inhibitor Cocktail, Sigma-Aldrich), 367 
followed by centrifugation at 16,000 × g for 10 min at 4°C to separate soluble and insoluble fractions. 368 
These were immediately fractionated by SDS PAGE on NuPAGE 4-12% Bis-Tris gels (Invitrogen). Gels 369 
were stained with Quick Blue Coomassie (Triple Red) then the entire gel cut into 24 equally-sized 370 
slices and proteins in excised slices subjected to tryptic digestion37. LC-MS/MS analysis was as 371 
described below.  372 
For pull-down analysis, frozen schizont preparations were thawed in the presence of 1% (v/v) 373 
Nonidet® P40 (CAS 68412-54-4, Santa Cruz Biotechnology), 10 mM EDTA and protease inhibitors 374 
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(cOmplete™ Protease Inhibitor Cocktail, Sigma-Aldrich) and extracted at 4°C for 1 h with intermittent 375 
vortexing.  The extracts were clarified by centrifugation at 16,000 × g for 10 min at 4°C, filtered 376 
through 0.22 μm PVDF centrifugal filter units (MilliporeSigma), then incubated with ~2 μg of the 377 
relevant anti-spectrin mAb for 1.5 h at 4°C with gentle mixing. Precipitation of immune complexes 378 
with Protein G Sepharose™ 4 Fast Flow (GE Healthcare) followed the manufacturer’s protocol. Bound 379 
complexes were subjected to SDS PAGE and stained bands of interest excised and analysed by tryptic 380 
digestion and LC-MS/MS. 381 
 382 
Mass spectrometry (LC-MS/MS) 383 
Tryptic digests were chromatographically resolved using an Ultimate 3000 RSLCnano (Dionex) with an 384 
EASY-Spray column (2 μm particle size, PepMap C18, 100 Å pore size, 50 cm x 75 μm ID; Thermo 385 
Scientific). Spectra were acquired using an LTQ Orbitrap Velos mass spectrometer (Thermo Scientific) 386 
acquiring the top 10 most intense ions in data dependent acquisition mode with CID fragmentation at 387 
35% normalised collision energy. For targeted work, data were acquired using an Orbitrap Fusion 388 
Lumos Tribrid mass spectrometer (Thermo Scientific) using a mixture of data dependent 389 
fragmentation and three targeted fragmentations (545.3006 Da, 659.8537 Da and 830.9363 Da for 390 
peptides FQIQDIVVQ, FQIQDIVVQTQ and FQIQDIVVQTQEGR, respectively) over a 3 sec cycle time. 391 
Dynamic exclusion was employed throughout to prevent repeat sampling of data dependent 392 
fragmentation. 393 
Data were searched using Mascot (Matrix Science) against the UniProt database, using trypsin 394 
or semi-trypsin as the cleavage enzyme, with a fixed carbamidomethylation modification (+57.021 Da) 395 
and variable methionine oxidation (+ 15.994 Da). A 10 ppm mass tolerance filter was applied for 396 
peptides with charge states +2 or above. Mascot search results were imported into Skyline38 to 397 
generate a spectral library for further quantitative processing of β-spectrin peptides. 398 
 399 
Statistical analysis  400 
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Prism 7 (GraphPad) was used for all statistical analysis. All experiments were performed at least twice, 401 
and statistical analysis was carried out by unpaired t-test of biological replicate or triplicate 402 
experiments. A p value of <0.05 was considered statistically significant. 403 
 404 
 405 
Data availability 406 
The data supporting the findings of this study are available within the paper and its Supplementary 407 
Information and are also available from the corresponding authors upon request.  408 
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Figure legends. 409 
Figure 1.  SUB1 and SERA6 are essential for asexual blood stage P. falciparum growth. a,  Architecture 410 
of floxed loci in SUB1HA3:loxP and SERA6:loxP parasites. Introduced loxP sites (arrowheads), 411 
recodonised sequence (hatched), HA3 epitope and known (SUB1) or predicted (SERA6) catalytic 412 
residues are indicated. Outcomes of rapamycin (RAP)-induced DiCre-mediated excision and positions 413 
of primers (half arrows) used for diagnostic PCR are indicated (see Supplementary Table 1 for primer 414 
sequences). Insets, PCR (representative of 4 independent experiments) confirming efficient gene 415 
excision by the end of cycle 0, ~44 h following mock-treatment (-RAP) or RAP-treatment (+RAP) of 416 
‘ring’-stage parasites. b, Western blots (representative of 2 independent experiments) showing 417 
ablation of SUB1 and SERA6 expression in cycle 0 schizonts. c, Light microscopic and IFA images of 418 
mature cycle 0 schizonts, showing normal parasite development and RAP-induced loss of SUB1HA3 419 
expression (representative of 6 independent experiments). Loss of SERA6 expression could not be 420 
similarly confirmed by IFA due to C-terminal tagging of SERA6 being unsuccessful and the lack of 421 
suitable SERA6-specific antibodies. Scale bar, 5 μm. DAPI, 4,6-diamidino-2-phenylindole. d, Replication 422 
of mock- and RAP-treated SUB1HA3:loxP and SERA6:loxP parasites over 2 erythrocytic cycles. 423 
Parasitaemia values (quantified by FACS) are averages from 2 biological replicates in different blood 424 
sources. Error bars, ±SD. e, PCR showing loss of ΔSUB1 (1 experiment) and ΔSERA6 (representative of 425 
2 independent experiments) parasites and outgrowth of non-excised parasites upon extended 426 
passage of RAP-treated cultures. f, Dot plots showing relative plaque forming ability (ratio of plaque 427 
numbers produced by RAP-treated cultures to those produced by mock-treated cultures, x100) of 428 
SUB1HA3:loxP and SERA6:loxP parasites without or following transfection with the indicated episomal 429 
expression plasmids. Statistical significance was determined by two-tailed t-test: SUB1HA3:loxPint: 430 
Empty vs WT complementation (t=7.702, d.f.=2, p=0.0164, 95% CI 4.636 to 16.73) n=2. SERA6:loxP: 431 
Empty vs WT complementation (t=19.65, d.f.=2, p=0.0026, 95% CI 68.39 to 107) n=2;  WT vs 432 
Cys644Ala complementation (t=30.96, d.f.=4, p<0.0001, 95% CI -94.44 to -78.81 ) n=3; WT vs 433 
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Uncleavable complementation (t=13.8, d.f.=4, p=0.0002, 95% CI -98.14 to -65.25) n=3. In all plots, 434 
central horizontal bar, mean. Error bars, ±SD. Significance levels: p≤0.001, ***; p≤0.01, **; p≤0.05, *.  435 
  436 
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Figure 2. SUB1 and SERA6 play distinct, sequential roles at egress. a, Left, stills from time-lapse DIC 437 
microscopic examination of control (-RAP) and RAP-treated (ΔSUB1) SUB1HA3:loxP schizonts 438 
following removal of C2; elapsed time indicated. Scale bar, 20 μm. Right, quantitation of PVM rupture 439 
in control and RAP-treated SUB1HA3:loxP schizont populations, collated from 5 videos of each from 2 440 
independent experiments (total number of observed PVM rupture events in control parasites, 226). 441 
PVM rupture is normalised to that in the controls (100% egress). Statistical significance determined by 442 
two-tailed t-test: -RAP vs +RAP (t=13.84, d.f.=2, p=0.0052, 95% CI -113.2 to -59.5); p≤0.01, **. b, 443 
Processing of SUB1 substrates is ablated in ΔSUB1 parasites. Western blot of C2-blocked 444 
SUB1HA3:loxP schizonts, or 30 min after washing away C2. Processed forms of SUB1 substrates are 445 
arrowed. c, Microneme discharge in ΔSUB1 parasites. IFA of C2-arrested parasites compared to 30 446 
min after washing away C2. Translocation of AMA1 to the intracellular merozoite surface is evident in 447 
the washed parasites. Scale bar, 10 μm. d, Invasion by control and RAP-treated SUB1HA3:loxP 448 
parasites under static and shaking conditions. Statistical significance by two-tailed t-test: -RAP 449 
stationary vs -RAP shaking (t=5.233, d.f.=5, p=0.0034, 95% CI 2.666 to 7.813 ) n=4;  +RAP start vs +RAP 450 
stationary (t=1.722, d.f.=5, p=0.1456, 95% CI -0.04104 to 0.2077) n=4; +RAP stationary vs +RAP 451 
shaking (t=0.4585, d.f.=5, p=0.6658, 95% CI -0.641 to 0.9193) n=4. Results shown are from 4 452 
biological replicate experiments (some dots are overlaid). e, Left, time-lapse DIC microscopic stills of 453 
control and RAP-treated SERA6:loxP schizonts following C2 removal. Scale bar, 20 μm. Right, 454 
quantitation of RBCM rupture. Data collated from 8 videos each of control and RAP-treated parasites, 455 
from 3 independent experiments (total number of observed rupture events in control parasites, 568). 456 
RBCM rupture is normalised to that in the controls (100% egress). Statistical significance  by two-457 
tailed t-test: -RAP vs +RAP (t=25.39, d.f.=4, p<0.0001, 95% CI -95.07 to -76.33) n = 3; p≤0.001, ***. f, 458 
Microneme discharge in arrested ΔSERA6 parasites. IFA of C2-arrested parasites compared with 30 459 
min after washing away C2. g, Disruption of the SERA6 gene has no effect on processing of SUB1 460 
substrates. h, Invasion efficiencies of the ΔSERA6 parasites under static and shaking conditions. 461 
Statistical significance by two-tailed t-test: -RAP stationary vs -RAP shaking (t=5.674, d.f.=4, p=0.0048, 462 
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95% CI 2.57 to 7.496) n=3; +RAP start vs +RAP stationary (t=2.741, d.f.=4, p=0.0518, 95% CI -0.004807 463 
to 0.7581) n=3; +RAP stationary vs +RAP shaking (t=2.526, d.f.=4, p=0.0649, 95% CI -0.1348 to 2.855) 464 
n=3; p≤0.01, **. Results shown are from 3 biological replicate experiments. In all plots, central bar, 465 
mean. Error bars, ±SD. Experiments in panels b, c, f and g were repeated twice, with reproducible 466 
results. 467 
 468 
Figure 3. SUB1 is required for PVM disruption and RBCM poration, whereas the ΔSERA6 phenotype 469 
mimics egress arrest with the cysteine protease inhibitor E64. a, Stills from simultaneous time-lapse 470 
DIC and fluorescence microscopic examination of typical control WT, ΔSUB1 and ΔSERA6 schizonts at 471 
the indicated intervals following removal of the egress inhibitor C2. PVM rupture and RBCM poration 472 
(indicated by access of phalloidin to the host RBC cytoskeleton) occurs in the ΔSERA6 parasites but 473 
not in the ΔSUB1 parasites, whilst RBCM rupture occurs in neither mutant.  Scale bar, 10 μm. b, TEM 474 
micrographs of an arrested ΔSUB1 schizont and a C2-arrested control cell, showing that the trapped 475 
merozoites are surrounded in both cases by an intact PVM and RBCM. Knob structures characteristic 476 
of the parasite-infected RBCM6 are indicated on its outer surface (arrow heads). The black dots are 477 
gold fiducials added for tomography. Scale bar, 500 nm. c, SEM images of ΔSERA6 schizonts before 478 
and 30 min following C2 removal, showing collapse of the RBCM around the intracellular merozoites 479 
in the washed sample. Scale bar, 5 μm. d, TEM micrographs of an arrested ΔSERA6 schizont and an 480 
E64-arrested control cell, showing in both remnants of ruptured PVM (asterisks) adjacent to the 481 
trapped merozoites. Knobs are highlighted as above (arrow heads). Scale bar, 500 nm. All experiments 482 
were repeated twice, with reproducible results. 483 
 484 
Figure 4. RBCM rupture is associated with rapid, SERA6-dependent cleavage of host RBC cytoskeleton β-485 
spectrin within its actin-binding domain. a, SDS PAGE showing appearance upon egress of mock-486 
treated (-RAP) SERA6:loxP schizonts of a high molecular mass species identified by Western blot and 487 
LC-MS/MS as truncated β-spectrin (reproducible in 15 independent experiments). b, Peptides (red) 488 
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identified by LC-MS/MS (3 technical replicate runs from a single biological experiment) of tryptic 489 
digests of polypeptide(s) enriched in the mock-treated SERA6:loxP schizont extract in the indicated 490 
region of the gel (~15-20 kDa), indicating egress-associated, SERA6-dependent cleavage of β-spectrin. 491 
A semi-tryptic peptide likely representing the C-terminus of the polypeptide(s) is in bold 492 
(Supplementary Fig. 6 shows fragmentation spectra). Calculated mass of the β-spectrin sequence 493 
(UniProtKB P11277) from Thr2-Gln167 is 19,251 Da. CH1, CH2, calponin homology domains. c, 494 
Appearance of a ~17 kDa N-terminal fragment of β-spectrin (arrowed) upon egress of mock-treated 495 
SERA6:loxP schizonts (reproducible in 4 independent experiments). d, Pull-down of cytoskeletal 496 
components from soluble extracts of egressing SERA6:loxP schizonts. Annotated species, including co-497 
precipitating β-actin, were identified by LC-MS/MS or Western blot (reproducible in 3 independent 498 
experiments). Peptide fingerprinting of the ~17 kDa β-spectrin CH1 domain was as in b. The presence 499 
of α-spectrin and full-length and truncated β-spectrin in pull-downs from the -RAP extracts indicates 500 
their SERA6-dependent dissociation from the normally insoluble cytoskeleton. Antibody heavy and 501 
light chains, asterisked. e, Fate of β-spectrin in SERA6:loxP schizonts following washing away a C2 502 
block (control) or with additional treatment by the indicated disruption methods. Cleavage never 503 
occurred in the absence of SERA6 (Western blot representative of 2 independent experiments). f, 504 
Architecture of RBC cytoskeleton spectrin heterotetramer, comprising 2 antiparallel αβ-spectrin 505 
heterodimers linked head-to-head (the right-hand dimer is abbreviated for clarity) which cross-link β-506 
actin-containing junctional complexes24. Spectrin repeat domains are numbered. Other structural 507 
features and positions of epitopes recognised by mAbs B-1, B-2 and VD4 are indicated. g, Top, SERA6-508 
dependent cleavage of β-spectrin should release each end of the αβ-spectrin tetramer from its 509 
cognate junctional complex. The cleaved CH1 domain may be released with actin still bound. Bottom, 510 
predicted global effect of SERA6-dependent cleavage on the cytoskeleton.  511 
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